Tom Cohen

What are the Key Challenges in Developing Bispecific Antibodies for Cancer Immunotherapy?

—

by

Tom Cohen
in

Are there too many opportunities in antibody-based immunotherapy? How do you choose your targets? How do you know when to kill a project?

Read More

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *